Diazyme kits incorporate PNA (peptide nucleic acid) technology:
This article was originally published in Clinica
Executive Summary
The Diazyme Laboratories division of General Atomics (La Jolla, California) introduced SNP detection kits for Factor V Leiden and MTHFR C667T at the American Association of Clinical Chemistry meeting in Chicago, Illinois last week. The kits incorporate peptide nucleic acid (PNA) technology licensed from Boston Probes (Bedford, Massachusetts). Factor V Leiden is the most common inherited coagulation disorder in the US population, and increases the risk of venous thrombosis in homozygous individuals up to 140-fold. The MTHFR C667T mutation is linked with DVT, heart attack and stroke.